Get the Stockscreener App
6.38
2.15%
-0.14
After Hours:
6.36
-0.02
-0.31%
Kezar Life Sciences Inc stock is traded at $6.38, with a volume of 71,717.
It is down -2.15% in the last 24 hours and down -14.82% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$6.52
Open:
$6.49
24h Volume:
71,717
Relative Volume:
0.70
Market Cap:
$46.55M
Revenue:
-
Net Income/Loss:
$-101.87M
P/E Ratio:
-5.5478
EPS:
-1.15
Net Cash Flow:
$-83.46M
1W Performance:
-5.48%
1M Performance:
-14.82%
6M Performance:
-3.57%
1Y Performance:
-24.95%
1-Day Range:
$6.35
$6.75
1-Week Range:
$6.16
$6.89
52-Week Range:
$5.202
$11.35
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.38 | 46.55M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Kezar Life Sciences Reports $20.3M Q3 Loss, Halts Key Lupus Trial Amid Safety Concerns - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar stock falls 11% after board rejects Concentra offer (update) - MSN
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK
Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India
Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):